

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

As of August 4th, 2025

SUNDAY, MAY 3, 2026

15:00 *Welcome Coffee & Registration*

15:30 – 18:30 **DRAVET SYNDROME FOUNDATION SPAIN**

15.30 **OPENING STATEMENTS**

15.40 **THE NEUROBIOLOGY OF COMORBIDITIES IN DRAVET SYNDROME**

Moran Rubinstein

16.05 **ADDRESSING GAPS IN GENETIC TESTING FOR DRAVET SYNDROME**

TBD

16:30 **UNDERSTANDING DISEASE MODIFICATION AND SYMPTOMATIC TREATMENTS FOR DRAVET SYNDROME**

Simona Giorgi

16:55 *Coffee Break*

17.15 **OUTCOME MEASURES: "SEIZURES AND NON-SEIZURES" IN CLINICAL TRIALS OF TREATMENTS FOR DEEs**

Elaine Wirrell

17.40 **THE IMPORTANCE OF MULTIDISCIPLINARY MANAGEMENTT IN DEEs**


Stéphane Auvin

18.05 **PATIENT-CENTERED HEALTHCARE: THE POWER OF PATIENT ADVOCACY**

José Ángel Aibar

18.30 **CLOSING REMARKS**

MONDAY, MAY 4, 2026



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

08:30 – 08:45 OPENING SESSION

08:45 – 10:45 Session 1: PRECLINICAL MODELS OF DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs): FROM SYMPTOMATIC TREATMENT TO DISEASE-MODIFYING AND PREVENTIVE STRATEGIES

Chairs: **Heidrun Potschka, *Munich, Germany***
Gabriele Lignani, *London, UK*

08:45 **FACE AND PREDICTIVE VALIDITY OF DEE MODELS: BASIS FOR ROBUST ASSESSMENT OF ANTISEIZURE EFFECTS**
Heidrun Potschka, *Munich, Germany*

09:05 Discussion

09:15 **IT'S NOT ALL ABOUT SEIZURES: ASSESSMENT OF EFFECTS ON NON-SEIZURE SYMPTOMS IN DEE MODELS** **Moran Rubinstein, *Tel-Aviv, Israel***

09:35 Discussion


09:45 **PRECISION MEDICINE APPROACHES FOR DEEs: TESTING STRATEGIES CONSIDERING SPECIES DIFFERENCES AND THE INFLUENCE OF GENETIC VARIANTS**
Jack M. Parent, *Ann Arbor, USA*

10:05 Discussion

10:15 **THE EARLIER – THE BETTER? - ASSESSMENT OF POSSIBLE DISEASE-MODIFYING AND PREVENTIVE STRATEGIES IN DEE MODELS**
Gabriele Lignani, *London, UK*

10:35 Discussion

10:45 *Coffee Break*



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA


MONDAY, MAY 4, 2026, (Cont.)

11:15 – 13:15 Session 2: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

- | | |
|-------|---|
| 11:15 | AZETUKALNER
Chris Kenney , <i>Xenon Pharmaceuticals, Canada</i> |
| 11:35 | Discussion |
| 11:45 | BEXICASERIN (LP352)
Tolga Uz , <i>Lundbeck Pharmaceuticals, Denmark</i> |
| 12:05 | Discussion |
| 12:15 | BHV-7000
Jason Lerner , <i>Biohaven Pharmaceuticals, USA</i> |
| 12:35 | Discussion |
| 12:45 | BL-001
Louis Licamele , <i>Bloom Science, USA</i> |
| 13:05 | Discussion |
| 13:15 | Lunch Break |

14:30 – 18:30 Session 3: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

- | | |
|-------|--|
| 14:30 | BMB-101
Stephen Collins , <i>Bright Minds Biosciences, USA</i> |
| 14:50 | Discussion |
| 15:00 | Elsunersen
Steve Petrou , <i>Praxis Precision Medicine, Australia</i> |
| 15:20 | Discussion |
| 15:30 | EPX -100
Anna Jeong , <i>Harmony Biosciences, USA</i> |
| 15:50 | Discussion |
| 16:00 | ES-481
ES-Therapeutics, USA
Presented by Terence O'Brien , <i>Monash University, Australia</i> |



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

16:20 Discussion

16:30 ETX101
Emma James, *Encoded Therapeutics, USA*

16:50 Discussion

17:00 Coffee Break

17:30 ION283 ASO
Berge Minassian, *University of Texas Southwestern, USA*

17:50 Discussion

18:00 Kv3.1 Targeted ASMs
Charles Large, *Autifony Therapeutics, UK*

18:20 Discussion

TUESDAY, MAY 5, 2026

08:30 – 11:30 Session 4: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

08:30 LRP-661 (Cannabidiol Derivatives)
Abdel-Rahman Lawendy, *London Research & Pharmaceuticals, Canada*

08:50 Discussion

09:00 NRTX-1001
Deborah M Kurrasch, *Stream Neuroscience Inc, USA*

09:20 Discussion


09:30 OV329
Julia Tsai, *Ovid Therapeutics, USA*

09:50 Discussion

10:00 PANX1 BLOCKERS
Panntherapi, France
Presented by **Gill Huberfeld**, *Hôpital Fondation Adolphe de Rothschild, France*

10:20 Discussion

10:30 RADIPRODIL
Russell L. Chin, *Neurvati Neurosciences, USA*



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA


- 10:50 Discussion
- 11:00 RAP 219
William Motley, *Rapport Therapeutics, USA*
- 11:20 Discussion
- 11:30 *Coffee Break*

12:00- 16:45 Session 5: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

- 12:00 SELETRACETAM
PrevEp, USA
Presented by **Wolfgang Löscher**, *Hannover Medical School, Germany and PrevEp, USA*
- 12:20 Discussion
- 12:30 SODIUM SELENATE
Terence O'Brien, *Monash University, Australia*
- 12:50 Discussion
- 13:00 SVG103
Sovargen Co, Republic of Korea
Presented by **Hing-Ho Lee**, *Korea Advanced Institute of Science and Technology (KAIST) and Sovargen Co, Republic of Korea*
- 13:20 Discussion
- 13:30 Lunch Break

14:45- 16:45 Session 5: NEW THERAPEUTIC AGENTS IN DEVELOPMENT (cont.)

- 14:45 SYNGAP 1 ASO
TBD, CAMP4 Therapeutics, USA
- 15:05 Discussion
- 15:15 VAL-1221
Dustin Armstrong, *Parasail LLC, USA*
- 15:35 Discussion
- 15:45 Vornatrigine (PRAX-628)
Steve Petrou, *Praxis Precision Medicine, Australia*
- 16:05 Discussion
- 16:15 ZOREVUNERSEN (STK-001)
TBD, Stoke Therapeutics, USA
- 16:35 Discussion



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

16:45 *Coffee Break*

17:15 – 18:15 Session 6: PROGRESS REPORT ON ANTISEIZURE DEVICES

17:15 VAGUS NERVE STIMULATION
Maxine Dibué-Adjei, *LivaNova, UK*

17:35 Discussion

17:45 NEUROSTIMULATION WITH FOCAL CORTEX STIMULATION
Precisis, *Germany*
Presented by **Andreas Schulze-Bonhage**, *University of Freiburg, Germany*

18:05 Discussion

WEDNESDAY, MAY 6, 2026

08:30-10:00 Session 6: PROGRESS REPORT ON RECENTLY MARKETED ANTISEIZURE MEDICATIONS

08:30 BRIVARACETAM
Brian Moseley, *UCB Pharma, Belgium*

08:50 Discussion

09:00 CENOBAMATE
John Paul Leach, *Angelini Pharma Group, Italy*

09:20 Discussion

09:30 FENFLURAMINE
Brian Moseley, *UCB Pharma, Belgium*


09:50 Discussion

10:00 – 12:00 Session 7: INNOVATIVE ROUTES OF RESCUE MEDICATION

10:00 DIAZEPAM NASAL SPRAY
Adrian L. Rabinowicz, *Neurelis, USA*

10:20 Discussion

10:30 PRECLINICAL AND CLINICAL EVIDENCE IN SUPPORT OF A DISEASE MODIFYING EFFECT OF DIAZEPAM TREATMENT ON SEIZURE CLUSTERS
Presented by **Steve White**, *School of Pharmacy, University of Washington, USA*



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA


E.C. Wirrell, USA

- 10:50 Discussion
- 11:00 BUCCAL MIDAZOLAM
TBD, *Neuraxpharm, Germany*
- 11:20 Discussion
- 11:30 STACCATO ALPRAZOLAM
Robert Roebling, *UCB Pharma, Belgium*
- 11:50 Discussion
- 12:00 *Coffee Break*

12:30 – 14:40 Session 8: DEVELOPING STATE-OF-THE-ART THERAPIES FOR DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs)

Chairs: **Andreas Brunklaus**, *Glasgow, UK*
Elaine Wirrell, *Rochester, USA*

- 12:30 SELECTING POPULATIONS FOR TRIALS OF ANTISEIZURE MEDICATIONS (ASMs) FOR DEEs – SHOULD WE LUMP OR SPLIT?
Elaine Wirrell, *Rochester, USA*
- 12:50 Discussion
- 13:00 MEASURING NONSEIZURE OUTCOMES IN CLINICAL TRIALS IN DEEs
J. Helen Cross, *London, UK*
- 13:20 Discussion
- 13:30 WHAT IS MEANT BY “DISEASE MODIFYING” AND HOW DO WE PROVE THAT?
Stephane Auvin, *Paris, France*
- 13:50 Discussion
- 14:00 METHODOLOGICAL CHALLENGES IN DEVELOPING GENE THERAPIES FOR DEEs
Andreas Brunklaus, *Glasgow, UK*
- 14:20 Discussion
- 14:30 Closing Remarks
- 14:40 *Light Lunch*



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com